aTyr Pharma, Inc.
Income Statement
| Line Item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $190.0K | $0 | $0 | $0 | $0 | $0 | $235.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $10.9M | $22.1M | $15.4M | $11.8M | $12.2M | $14.8M | $14.0M | $13.4M |
| SG&A Expense | $3.9M | $4.8M | $4.9M | $4.0M | $3.6M | $3.3M | $3.3M | $3.5M |
| Operating Income | $-14.8M | $-26.7M | $-20.3M | $-15.8M | $-15.8M | $-18.1M | $-17.3M | $-16.6M |
| Operating Margin | — | -14,076.3% | — | — | — | — | — | -7,079.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-14.0M | $-25.7M | $-19.5M | $-14.9M | $-15.0M | $-17.3M | $-16.3M | $-15.5M |
| Net Margin | — | -13,549.5% | — | — | — | — | — | -6,591.9% |
| EPS (Basic) | $-0.15 | $-0.26 | $-0.22 | $-0.17 | $-0.17 | $-0.23 | $-0.23 | $-0.23 |
| EPS (Diluted) | $-0.15 | $-0.26 | $-0.22 | $-0.17 | $-0.17 | $-0.23 | $-0.23 | $-0.23 |
| Shares Outstanding (Basic) | 93.0M | 97.2M | 90.1M | 86.5M | 74.3M | 75.8M | 72.3M | 66.1M |
| Shares Outstanding (Diluted) | 93.0M | 97.2M | 90.1M | 86.5M | 74.3M | 75.8M | 72.3M | 66.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |